Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax + Azacitidine + DLI in High-Risk AML Post-HCT
NCT06158100Phase 1Terminated
- Start
- Dec 2024
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of venetoclax in acute myeloid leukemia (AML) (2 cohorts). Primary endpoints: Recommended Phase 2 Dose up to 13 months and Number of Participants Experiencing Treatment-Related Toxicity up to 13 months. Started Dec 2024; status: terminated.
02
Drugs
venetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06158100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06158100.